Summary of Purpose
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke and presenting with microembolic signals (MES) receive either Revacept (single dose) plus antiplatelet monotherapy (Aspirin or Clopidogrel) or monotherapy alone with the aim of reducing MES. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. The...Read More →
The following dates are available for this trial. Trial information last updated on 4 November 2013.
|1 Mar 2013||16 Jul 2012||1 Sep 2014||1 Dec 2014||1 Nov 2013||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Conditions See All
- AdvanceCor GmbH Lead
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
- Holger Poppert, PD Dr. med.